Amgen's TEPEZZA Approved In Japan For Treatment Of Active Thyroid Eye Disease
25/9 04:55
(RTTNews) - Amgen (AMGN) said that Japan's Ministry of Health, Labour and Welfare approved TEPEZZA (Teprotumumab) for the treatment of active or high clinical activity score (CAS) Thyroid Eye Disease or TED....